Cellectar Biosciences and NorthStar Medical Radioisotopes have signed a strategic supply agreement for the procurement of NorthStar’s non-carrier added (n.c.a.) Ac-225, the company announced today. “We plan to advance CLR…
NorthStar Medical Radioisotopes has expanded its strategic collaboration with Convergent Therapeutics, the company announced recently. According to a release, NorthStar will: Provide Convergent with Ac-225 for use in CONVO1-a, Use…
NorthStar Medical Radioisotopes has entered into a sponsorship agreement with an undisclosed major U.S. research institution, which will undertake an investigator-initiated research project titled, “Program to Find a Cure for…
NorthStar Medical Radioisotopes and BWXT Medical Ltd., have signed a master services agreement that will facilitate the production of actinium-225 (Ac-225), a medical isotope used to kill cancer cells while…
NorthStar Medical Radioisotopes has amended and expanded its existing collaboration with Monopar Therapeutics, the company announced recently. According to a release, the long-term, non-exclusive master supply agreement states that NorthStar…
NorthStar Medical Radioisotopes is signing a clinical supply agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials, the company recently…
NorthStar Medical Radioisotopes has expanded its strategic collaboration with Curadh, the organization announced today. According to a release, under the new agreement, NorthStar will manufacture and distribute patient doses for…
NorthStar Medical Radioisotopes has established a partnership with Curadh MTR Inc., a global molecularly targeted radiation (MTR)-focused organization, the company announced recently. According to a release, NorthStar will supply its…
NorthStar Medical Radioisotopes announced today the first patient to be treated using the radioisotope Copper-67 (Cu-67) produced from its electron accelerator. According to a release, the administration of the therapeutic…
NorthStar Medical Radioisotopes announced today that it will provide Bayer with its environmentally preferred, non-carrier added (n.c.a.) therapeutic medical radioisotope, actinium‐225 (Ac‐225). “We are very pleased to enter this Ac-225…
